2,531
Participants
Start Date
February 28, 2006
Primary Completion Date
January 31, 2007
Study Completion Date
January 31, 2007
Rivaroxaban (BAY59-7939)
10 mg rivaroxaban (tablet) once daily administered for 13 +/- 2 days
Enoxaparin
Syringe of enoxaparin at a dose of 40 mg for 13 +/- 2 days
Vienna
Frederiksberg
Antwerp
Randburg
Johannesburg
Merksem
Kongsvinger
Elverum
Lillehammer
Herlev
Gjøvik
Reet
Hellerup
Newcastle
Pellenberg
Hasselt
Liège
Linz
Durban
Innsbruck
Worcester
Somerset West
Namsos
Graz
Silkeborg
Roeselare
Bloemfontein
Castellon
Marseille
Sommerfeld
Soyaux
San Donato Milanese
Varese
Jaén
Lecco
Madrid
Bremen
Alcorcón
Chihuahua, Chih.
Pamplona
Haifa
Udine
Abano Terme
Padua
Bologna
Düsseldorf
Parma
Nantes
Guadalajara
Kfar Saba
Valencia
Florence
Tel Litwinsky
Vandœuvre-lès-Nancy
Holon
Witten
Frankfurt am Main
Brno
Liévin
Clermont-Ferrand
Tel Aviv
Frankfurt am Main
Ẕerifin
Paris
Paris
Paris
Paris
Bois-Guillaume
Rheinfelden
Garmisch-Partenkirchen
Hermosillo
Beersheba
Fürth
Würzburg
Bad Mergentheim
Monaco
Beijing
Beijing
Beijing
Shanghai
Shanghai
Shanghai
Penticton
Saint John
Burlington
Kitchener
Oakville
Oshawa
Ottawa
Peterborough
Scarborough Village
Windsor
Bogotá
Medellín
Santiago de Cali
Pretoria
Prague
Chomutov
Havlíčkův Brod
Jihlava
Kolín
Pardubice
Pilsen
Hørsholm
Nice
Nice
Gubbio
Alghero
Roma
Amsterdam
Hilversum
Hoofddorp
Leiden
Nijmegen
Oss
Zwolle
Callao
Lima
Lima
Bialystok
Bydgoszcz
Gdansk
Krakow
Lodz
Lublin
Lublin
Szczecin
Warsaw
Warsaw
Pretoria
Pretoria
Badalona
Barcelona
Barcelona
Barcelona
Falköping
Gothenburg
Halmstad
Hässleholm
Jönköping
Kungälv
Lidköping
Varberg
Lead Sponsor
Bayer
INDUSTRY